non-small cell lung cancer
Conditions
Interventions
Test group:Sequential maintenance therapy with PD-1/CTLA-4 bispecific antibody and anlotinib after combination of PD-1/CTLA-4 bispecific antibody and chemotherapy
Sponsors
The First Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Histologically or cytologically confirmed non-small cell lung cancer (NSCLC), and driver gene negative; 2. Subjects whose first-line treatment failed and who have not used the Aito combination antibody or O+Y regimen; 3. Subjects must have measurable target lesions assessed by CT or MRI. 4. Expected survival >=3 months.
Exclusion criteria
Exclusion criteria: 1. Driver gene positive; 2. First-line treatment using Nivolumab and Ipilimumab (O+Y) regimen or QL1706 or Cadonilimab; 3. Within 2 weeks prior to the first dose, systemic use of corticosteroids or other immunosuppressive drugs; 4. Developed other malignant tumours within =5 years before the first dose; 5. Presence of any active autoimmune disease or a history of autoimmune disease that may recur.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival, PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate, DCR;Duration of relief, DOR;Objective response rate, ORR; | — |
Countries
China
Contacts
Public ContactJuntao Zou
The First Affiliated Hospital of Nanchang University
Outcome results
None listed